Elotuzumab: no benefit for older patients with newly diagnosed multiple myeloma
Mené sur 748 patients atteints d'un myélome multiple récemment diagnostiqué et inéligibles à une greffe de cellules souches hématopoïétiques (âge médian : 73 ans), cet essai international de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout de l'élotuzumab à un traitement combinant lénalidomide et dexaméthasone
Major progress has been made in the treatment of older patients (≥65 years) with newlydiagnosed multiple myeloma. To date, continuous lenalidomide-based regimens are consideredas standard of care for transplantation-ineligible patients with newly diagnosed multiplemyeloma. In the past 10 years, immunotherapy was established as a new cornerstone of myelomatherapy, in addition to proteasome inhibitors and immunomodulatory drugs. The incorporationof daratumumab, a monoclonal antibody targeting CD38, with lenalidomide and dexamethasoneled to progression-free and overall survival improvement in older patients with newlydiagnosed multiple myeloma. Elotuzumab, a monoclonal antibody targeting SLAMF7, was approved in combination withlenalidomide and dexamethasone for the treatment of patients with relapsed and refractorymyeloma. The role of elotuzumab in a front-line setting is a key question in the field ofmyeloma.
The Lancet Haematology , commentaire, 2021